Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

The Delhi High Court refused to stop an earlier order that lets Dr Reddy's make Semaglutide in India only for export, saying ...

Novo Nordisk has approached the Delhi High Court to prevent Dr Reddy’s Laboratories from manufacturing and exporting ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...

Semaglutide, a GLP-1 receptor agonist (RA), was associated with a significantly lower risk for adult-onset epilepsy in patients with diabetes than other glucose-lowering drugs (GLDs). Notably, this ...

The fresh plea follows a recent court order allowing Dr. Reddy’s Laboratories (DRL) to continue manufacturing and exporting ...

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by ...

Novo Nordisk has intensified its legal push in India by filing a plea against Sun Pharma, seeking to delay competition in the ...